Home / Health / Regeneron Drug Fights Muscle Waste in Obesity Trials
Regeneron Drug Fights Muscle Waste in Obesity Trials
1 Oct
Summary
- Experimental drug trevogrumab reduced muscle loss by 50%.
- Study presented at European Association for the Study of Diabetes conference.
- Trevogrumab may help rebuild lost muscle mass, data suggests.
An experimental drug from Regeneron, trevogrumab, demonstrated a 50% reduction in muscle mass loss when used alongside Novo Nordisk's popular semaglutide. This finding, presented at the European Association for the Study of Diabetes conference in Milan, addresses a key concern with current weight-loss treatments: the significant loss of lean muscle. The study involved nearly 1,000 patients aged 18 to 65.
Trevogrumab inhibits myostatin, a protein linked to muscle wasting. In the trial, adding a 75-milligram dose of trevogrumab preserved over 70% of muscle mass compared to semaglutide alone. Notably, when patients stopped semaglutide but continued trevogrumab, their muscle mass appeared to return to baseline levels, suggesting a muscle-rebuilding capability.
Regeneron plans further studies with the 75-mg dose, including a trial for patients over 65, focusing on enhancing the quality of weight reduction. While a combination with another Regeneron drug, garetosmab, was discontinued due to safety concerns, trevogrumab alone exhibited a similar safety profile to semaglutide.
